March 22 (Reuters) - Prometic Life Sciences Inc PLI.TO
* Confirms PBI-4050's positive effects on novel biomarkers
in patients suffering from metabolic syndrome and Type 2
diabetes
* Statistically significant decrease in novel biomarkers
associated with a high risk of cardiovascular events
* Results further support PBI-4050's pharmacological
activity and clinical benefits in patients
* PBI-4050 has demonstrated a "very good" safety and
tolerability profile, with no drug-related serious adverse
events
Source text for Eikon: ID:nPn1jC7v1a
Further company coverage: PLI.TO
(Bengaluru Newsroom: +1-646-223-8780)